SLRX Salarius Pharmaceuticals Inc Final Profit

Costs for data analysis automation and robotic molecule screening impact efficiency, and the net income of Salarius Pharmaceuticals (SLRX) on this chart on GURU.Markets shows that the latest parameter is -0.01. Growth relies on the success of seclidemstat and patent protection, while financial potential is based on the procurement of rare cancer therapies by health insurers.

This indicator captures the daily revenue balance after deducting all operating and tax expenses under GAAP standards, allowing for an assessment of the business's actual solvency without quarterly adjustments. By analyzing the reported net income of Salarius Pharmaceuticals (SLRX), an investor can determine whether the company has sufficient resources for costly oncology clinical trials or if capital is being depleted due to the high cost of developing orphan drugs.